| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3265053 | Digestive and Liver Disease | 2009 | 5 Pages |
BackgroundIn developed countries hepatitis C is prevalently transmitted by intravenous drug users (IDUs). The problems associated with management of HCV hepatitis in these patients have, in the past, discouraged treatment.AimTo evaluate efficacy, safety and tolerability of a standard Peginterferon (Peg-IFN) α-2b or α-2a plus Ribavirin treatment in IDUs who were receiving methadone or buprenorphine.MethodsA multi-centre prospective observational study performed from September 2003 to September 2006 in Central Italy (Umbria and Marches regions). A shared care model of HCV management was used which integrated a multidimensional, multidisciplinary approach.ResultsSixty-five subjects were evaluated and 52 satisfied inclusion criteria. Forty-five completed treatment (25 with Peg-IFN α-2b, 20 with Peg-IFN α-2a), a total of 37 showed a biochemical/virological response at the end of treatment (ITT 71.1%), 26 had a sustained virological response (ITT 50%; 38.4% of cases genotype 1-4, 61.6% genotype 3-2).ConclusionsThe results indicate that patients on maintenance treatment with methadone/buprenorphine can be treated for HCV. The success rate was fairly good; tolerability and side effects were similar to those reported in non-IDU patients. Close cooperation with specialists in drug addiction and psychiatrists is however essential for success.
